#PeptideTherapy #BPC157 #MetabolicHealth #VitalityOptimization #FunctionalMedicine #CDRXPharmacy #CompoundingPartners To view or add a comment, sign in The FDA has granted Priority Review to asundexian, an investigational oral factor XIa inhibitor manufactured by Bayer, for secondary stroke prevention after noncardioembolic ischemic stroke or transient ischemic attack
scar tissue reduction begins Weeks 1012: full healing potential of the protocol - this is when chronic injury patients see the most dramatic change Do not stop after the loading phase when you "feel better." The maintenance phase is when tissue quality actually improves - stopping early means trading short-term pain relief for inferior long-term repair
The compound also appears to reduce hepatic steatosis (fatty liver) by enhancing hepatic fatty acid oxidation and reducing lipogenesis
Clinical Update 5/05/2020 CBD for Osteoarthritis Pain A recent study, conducted in dogs, showed promise for CBD in reducing pain and inflammation due to osteoarthritis (pain due to worn joints)
BPC-157 studies have not shown evidence of this at tested doses, and some data suggests it may actually exert anti-tumor effects through indirect mechanisms including immune modulation
